Intravenous (IV) Iron Drugs - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as:

- Actavis, Inc.
- AMAG Pharmaceuticals, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Galenica Ltd.
- Luitpold Pharmaceuticals, Inc.

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK
IV Iron Drugs Market
A Quick Primer
US and Europe Dominate IV Iron Market
Asia-Pacific
The Fastest Growing Market
Recession Fails to Affect Market Growth
Positive Outlook for the Healthcare Industry Signals Prospects
Table 1: Healthcare Spending as a Percentage of GDP in Select Countries (includes corresponding Graph/Chart)

2. INDUSTRY OVERVIEW & TRENDS
IDA and Treatment
An Overview
Dialysis Clinics
Major Market for IV Iron Supplements
Table 2: World Distribution of Dialysis Patients by Country (2013): Number of Patients in Thousands for Brazil, China, Japan, Mexico, US and Others (includes corresponding Graph/Chart)
Table 3: World Dialysis Prevalence by Country (2013): Prevalence in Patients per Million Population for Brazil, China, Japan, Mexico, US and Others (includes corresponding Graph/Chart)
Table 4: Global Iron Deficiency Anemia Prevalence by Risk Groups
Preschool Children, School-age Children, Pregnant Women, Non-Pregnant Women, Men and Elderly
Analyzed by Prevalence Percentage (includes corresponding Graph/Chart)
Table 5: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN)
(includes corresponding Graph/Chart)
IV Iron Drugs
An Overview
Select IV Iron Drugs Prescribed for Iron Deficiency
Table 6: Global Sales of Select IV Iron Drugs in US$ Million: 2013 (includes corresponding Graph/Chart)
Galenica
The Global Leader in IV Iron
Venofer®
Galenica's Wonder Drug
Venofer Continues to Lose Ground
Ferinject/Injectafer
A Promising Revenue Spinner for Galenica
Feraheme Surges Ahead; Manufacturer Eyes Expansion of Indications
The Vulnerable Ageing Population Supports Demand
Table 7: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013E (includes corresponding Graph/Chart)
Changing Preferences Favor IV Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
Chronic Kidney Disease
The Predominant Growth Factor
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
Anemia in Heart Failure
A Market with Huge Potential
Chemotherapy Induced Anemia to Promote IV Iron Supplements
Table 8: Global Cancer Incidence by Region (2012): Number of New Cancer Cases for Asia-Pacific, Europe, North and South America, and Africa (includes corresponding Graph/Chart)
Correction of IDA in Pregnancy Signals Opportunities
Women's Health
Key Growth Opportunity
Perioperative and Postoperative Anemia
A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Peginesatide
A Possible Threat to IV Iron
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW
Increasing Trend towards Bundled Reimbursements
A Glimpse of Regulations in the US and Europe
Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS
Iron
A Vital Element
Iron-Deficiency Anemia
Intravenous Therapy
Patients of Chronic Illnesses, the Elderly and Women
The High Risk Population
Treatment for Iron Deficiency Anemia
Iron Requirement in Chronic Kidney Disease
Classification of Iron Deficiency in CKD
Treating Iron Deficiency in CKD Patients
Side Effects of Iron Supplementation in CKD
Methods of Restoring Iron
Oral Iron Therapy
IV Iron-Infusion Therapy
Intravenous (IV) Iron
Conditions for Receiving Iron Injections
Injection Procedure
Categories of Iron Injections
Suitability of IV Iron Preparation
Suitability of Regimen
Management of Iron Doses
Effectiveness of Iron Injection
Requirement of Test Dose
Adverse Effects of Iron Injections
Iron Therapy: Caution
Duration of Iron Infusion
Iron Overdose
Iron-Out-of-Balance Therapies
Blood Donation
Therapeutic Phlebotomy
Red Cell Apheresis
Iron Chelation Therapy
Iron-Chelating Drugs
Desferrioxamine or Desferal
Deferiprone or Ferriprox
Conditions for Undergoing Iron Chelation Therapy
Kinds of Chelation Therapy
Side Effects Caused by IV Iron Chelation

5. PRODUCT LAUNCHES/APPROVALS
FDA approves Injectafer® for the Treatment of IDA
Takeda Pharmaceutical Company Introduces Rienso® in Europe
Pharmacosmos Launches Monofer® Intravenous Iron Drug

6. RECENT INDUSTRY ACTIVITY
American Regent Steps Up Injectafer® Promotions
AMAG Files for Rienso Label Expansion in Europe
AMAG Receives FDA Complete Response Letter for Feraheme®
Vifor Pharma and Zeria Pharmaceutical Co., Ltd. Sign Exclusive Licensing Agreement for Ferinject® in Japan
Watson Pharmaceuticals Changes Name to Actavis
Luitpold Pharmaceuticals Obtains FDA Acceptance for Review of Injectafer® NDA
AMAG Pharmaceuticals Receives FDA Acceptance for Feraheme® sNDA Review
Takeda Issues Rienso Recall in Switzerland
EC Approves Takeda’s Rienso® to Treat Anemia
BioLink Life Sciences to Commence Phase I Trial of FCP

7. FOCUS ON SELECT PLAYERS
Actavis, Inc. (US)
AMAG Pharmaceuticals, Inc. (US)
Fresenius Medical Care AG & Co. KGaA (Germany)
Galenica Ltd. (Switzerland)
Vifor Pharma Ltd. (Switzerland)
Luitpold Pharmaceuticals, Inc. (US)
American Regent, Inc. (US)
Pharmacosmos A/S (Denmark)
Sanofi US (US)
Takeda Pharmaceutical Company Limited (Japan)

8. GLOBAL MARKET PERSPECTIVE
Table 9: World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 10: World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 11: World 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A. Market Analysis
   Current & Future Analysis
   CKD Fuels the US Market for IV Iron
   Addressing Broader IDA Indicates Opportunities
   CMS Reimbursement Shifts to Bundled Payment for Dialysis
   Comparison of the Old (Fixed Payment) and Bundled Payment Reimbursement Models
   The Anticipated Effect of Bundling Reimbursement on Clinical Practice
   ESRD QIP Related Measures for the Years 2012, 2013 and 2014
   Concerns over Allergic Reactions Prompts FDA to Issue Warning
   Potential Short-Term and Long-Term Safety Concerns of IV Iron Preparations
   Competitive Scenario
   Table 12: Leading IV Iron Drugs in the US Market (2013): Percentage Breakdown of Value Sales for Feraheme, Ferrlecit, Venofer and Others (includes corresponding Graph/Chart)
   Table 13: Leading Drugs in the US Non-Dialysis IV Iron Market (2011 & 2013): Percentage Breakdown of Volume Sales for Feraheme, Ferrlecit + Generic Ferric Gluconate, Venofer and Others (includes corresponding Graph/Chart)
   Table 14: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Share of Patients with ID and IDA for Select Diseases (includes corresponding Graph/Chart)
   Table 15: Preferred Therapy for New ESRD Patients in the US: Percentage Breakdown by Number of Patients Opting for Hemodialysis, Transplant and Peritoneal Dialysis (includes corresponding Graph/Chart)
   Does Dose Limitation Affect Venofer's Sales?
   Product Approval
   Strategic Corporate Developments

B. Market Analytics

Key Players
Table 23: European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region/Country
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 24: European Historic Review for Intravenous (IV) Iron Drugs by Geographic Region/Country
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 25: European 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region/Country
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
4a. FRANCE
Market Analysis
Table 26: French Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 27: French Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
4b. GERMANY
A. Market Analysis
Current & Future Analysis
Fresenius Medical Care Ag & Co. Kgaa
A Key Player
B. Market Analytics
Table 28: German Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 29: German Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 30: Italian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 31: Italian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
Market Analysis
Table 32: UK Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 33: UK Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
4e. SPAIN
Market Analysis
Table 34: Spanish Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 35: Spanish Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
4f. RUSSIA
Market Analysis
Table 36: Russian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 37: Russian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
4g. REST OF EUROPE
A. Market Analysis
Current & Future Analysis
IV Iron Market in Switzerland
Table 38: Swiss IV Iron Market by Therapeutic Area: Percentage Breakdown of Value Sales for Cardiology, Gastroenterology, Geriatry, Gynaecology, Internal Medicine, Nephrology, Oncology, and Others (includes corresponding Graph/Chart)
Product Launch
Strategic Corporate Development
Key Players
B. Market Analytics
Table 39: Rest of European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding...
Table 40: Rest of European Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC Market Analysis
Table 41: Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region/Country China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 42: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region/Country China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 43: Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region/Country Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
5a. CHINA Market Analysis
Table 44: Chinese Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 45: Chinese Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5b. INDIA Market Analysis
Table 46: Indian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 47: Indian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC Market Analysis
Table 48: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 49: Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. LATIN AMERICA Market Analysis
Table 50: Latin American Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 51: Latin American Historic Review for Intravenous (IV) Iron Drugs by Geographic Region Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 52: Latin American 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD Market Analysis
Table 53: Rest of World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 54: Rest of World Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 17 (including Divisions/Subsidiaries 20)
The United States (6)
Japan (2)
Europe (5)
Germany (1)
Rest of Europe (4)
Asia-Pacific (Excluding Japan) (7)

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/1382362/](http://www.researchandmarkets.com/reports/1382362/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Intravenous (IV) Iron Drugs - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/1382362/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 6930</td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td>USD 9405</td>
</tr>
<tr>
<td>1 - 10 Users:</td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ____________ Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World